title: [The baseline characteristics of patients with type 2 diabetes initiating insulin detemir : the Chinese cohort from the SOLVE(TM) study].
abstract: OBJECTIVE
  To characterize the baseline status of Chinese diabetic patients based on data derived from Chinese cohort from SOLVE(TM) study.
  
  
  METHODS
  Patients with type 2 diabetes initiating basal insulin detemir at the decision of the physician were eligible for the study. Data on demographics, medical history, glycemic profile and treatment regimen at baseline were collected by physicians.
  
  
  RESULTS
  A total of 3272 patients [female 42%, male 58%, mean age (56.2 ± 10.8) years] were included in the study. Their BMI was (25.3 ± 3.3) kg/m(2). The duration of diabetes was 4.0 (0.1 - 27.0) years, and the duration of treatment with oral antidiabetic drugs (OADs) was 3.0 (0.0 - 20.2) years. The proportions of subjects with diabetic macro- and micro-vascular complications were 15.8% (515 cases) and 27.1% (866 cases), respectively. The hemoglobin A1c (HbA1c) at baseline was (8.33 ± 1.70)%, and the fasting blood glucose (FPG) was (9.5 ± 2.6) mmol/L.
  
  
  CONCLUSIONS
  A large proportion of patients with type 2 diabetes remain in poor glycemic control, and the prevalence of diabetic complications is high, which requires optimal therapeutic strategy for the patients with suboptimal glycemic control.
authors: Department of Endocrinology, Chinese PLA General Hospital, Beijing, China. panchy301@yahoo.com.cn
authors: Chang-yu
authors: CY
authors: Pan
authors: Li-nong
authors: LN
authors: Ji
authors: Ju-ming
authors: JM
authors: Lu
authors: Wen-ying
authors: WY
authors: Yang
authors: Zhi-guang
authors: ZG
authors: Zhou
authors: Da-jin
authors: DJ
authors: Zou
authors: Qiu-he
authors: QH
authors: Ji
authors: Ping
authors: P
authors: Han
authors: Jie
authors: J
authors: Liu
authors: Qiang
authors: Q
authors: Li
authors: Ben-li
authors: BL
authors: Su
authors: Yan-bing
authors: YB
authors: Li
authors: Zheng-nan
authors: ZN
authors: Gao
authors: Peng-hua
authors: PH
authors: Wang
authors: Shi-nan
authors: SN
authors: Yin
authors: Yan-hu
authors: YH
authors: Dong
authors: Tao
authors: T
authors: Yang
authors: Kan
authors: K
authors: Sun
authors: Hong
authors: H
authors: Li
authors: Xu
authors: X
authors: Hong
authors: Jing
authors: J
authors: Lin
authors: Jing-mei
authors: JM
authors: Shi
authors: Xiao-Jie
authors: XJ
authors: Yang
authors: Hui
authors: H
authors: Fang
authors: Xiao-dong
authors: XD
authors: Yan
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; C517652:hemoglobin A1c protein, human